1. World Health Organisation (WHO), Cancer pain relief. 2nd ed, Geneva, 1996.
2. Ventafridda V, Tamburini M, Caraceni A, et al., A validation study of the WHO method for cancer pain relief, Cancer, 1987;59:850–6.
3. Zeppetella G, O'Doherty CA, Collins S, Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice, Palliat Med, 2001;15:243–6.
4. Fishbain DA, Cole B, Lewis J, et al., What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review, Pain Med, 2008;9:444–59.
5. Breivik H, Cherny N, Collett B, et al., Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes, Ann Oncol, 2009;20:1420–33.
6. Portenoy RK, Hagen NA, Breakthrough pain: definition, prevalence and characteristics, Pain, 1990;41:273–81.
7. Payne R, Recognition and diagnosis of breakthrough pain, Pain Med, 2007;8 Suppl 1:S3–7.
8. Svendsen KB, Andersen S, Arnason S, et al., Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms, Eur J Pain, 2005;9:195–206.
9. Hojsted J, Nielsen PR, Eriksen J, et al., Breakthrough pain in opioid-treated chronic non-malignant pain patients referred to a multidisciplinary pain centre: a preliminary study, Acta Anaesthesiol Scand, 2006;50:1290–6.
10. Davies AN, Dickman A, Reid C, et al., Breakthrough cancer pain, BMJ, 2008;337:a2689.
11. Caraceni A, Martini C, Zecca E, et al., Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey, Palliat Med, 2004;18:177–83.
12. Portenoy RK, Payne D, Jacobsen P, Breakthrough pain: characteristics and impact in patients with cancer pain, Pain, 1999;81:129–34.
13. Hwang SS, Chang VT, Kasimis B, Cancer breakthrough pain characteristics and responses to treatment at a VA medical center, Pain, 2003;101:55–64.
14. Portenoy RK, Managing cancer pain poorly responsive to systemic opioid therapy, Oncology (Williston Park), 1999;13:25–9.
15. Mercadante S, Radbruch L, Caraceni A, et al., Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care, Cancer, 2002;94:832–9.
16. Fine PG, Busch MA, Characterization of breakthrough pain by hospice patients and their caregivers, J Pain Symptom Manage, 1998;16:179–83.
17. Levy MH, Pharmacologic treatment of cancer pain, N Engl J Med, 1996;335:1124–32.
18. Zeppetella G, O'Doherty CA, Collins S, Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice, J Pain Symptom Manage, 2000;20:87–92. 19. Portenoy RK, Bruns D, Shoemaker B, et al., Breakthrough pain
in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics, J Opioid Manag, 2010;6:97–108.
20. Fortner BV, Okon TA, Portenoy RK, A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain, J Pain, 2002;3:38–44.
21. Portenoy RK, Bennett DS, Rauck R, et al., Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain, J Pain, 2006;7:583–91.
22. Gureje O, Von Korff M, Simon GE, et al., Persistent pain and well-being: a World Health Organization Study in Primary Care, JAMA, 1998;280:147–51.
23. Kirsh KL, Whitcomb LA, Donaghy K, et al., Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study, Clin J Pain, 2002;18:S52–60.
24. Zeppetella G, Ribeiro MD, Pharmacotherapy of cancer-related episodic pain, Expert Opin Pharmacother, 2003;4:493–502.
25. McMillan SC, Tofthagen C, Morgan MA, Relationships among pain, sleep disturbances, and depressive symptoms in outpatients from a comprehensive cancer center, Oncol Nurs Forum, 2008;35:603–11.
26. Abernethy AP, Wheeler JL, Fortner BV, A health economic model of breakthrough pain, Am J Manag Care, 2008;14:S129–40.
27. Grant M, Ferrell BR, Rivera LM, et al., Unscheduled readmissions for uncontrolled symptoms. A health care challenge for nurses, Nurs Clin North Am, 1995;30:673–82.
28. Fortner BV, Demarco G, Irving G, et al., Description and predictors of direct and indirect costs of pain reported by cancer patients, J Pain Symptom Manage, 2003;25:9–18.
29. Caraceni A, Portenoy RK, An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain, Pain, 1999;82:263–74.
30. Fishman B, Loscalzo M, Cognitive-behavioral interventions in management of cancer pain: principles and applications, Med Clin North Am, 1987;71:271–87.
31. Daut RL, Cleeland CS, Flanery RC, Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases, Pain, 1983;17:197–210.
32. Serlin RC, Mendoza TR, Nakamura Y, et al., When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function, Pain, 1995;61:277–84.
33. Portenoy RK, Miransky J, Thaler HT, et al., Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect, Cancer, 1992;70:1616–24.
34. Beck AT, Ward CH, Mendelson M, et al., An inventory for measuring depression, Arch Gen Psychiatry, 1961;4:561–71.
35. Beck AT, Epstein N, Brown G, et al., An inventory for measuring clinical anxiety: psychometric properties, J Consult Clin Psychol, 1988;56:893–7.
36. Yates JW, Chalmer B, McKegney FP, Evaluation of patients with advanced cancer using the Karnofsky performance status, Cancer, 1980;45:2220–4.
37. Davies AN, Dickman A, Reid C, et al., The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland, Eur J Pain, 2009;13:331–8.
38. Bennett D, Burton A, Fishman S, Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1: Assessment., Pharm Therap, 2005;30:296–301.
39. Akerman B, Arwestrom E, Post C, Local anesthetics potentiate spinal morphine antinociception, Anesth Analg, 1988;67:943–8.
40. Foley KM, Inturrisi CE, Analgesic drug therapy in cancer pain: principles and practice, Med Clin North Am, 1987;71:207–32.
41. Hanks GW, The pharmacological treatment of bone pain, Cancer Surv, 1988;7:87–101.
42. Portenoy RK, Practical aspects of pain control in the patient with cancer, CA Cancer J Clin, 1988;38:327–52.
43. Tuttle CB, Drug management of pain in cancer patients, Can Med Assoc J, 1985;132:121–34.
44. Zeppetella G, Breakthrough pain should be distinguished from background pain, Guidelines in Practice, 2009;12(3). Available at: http://www.breakthroughcancerpain.org/healthprofessionals
/painmanagement/Zeppetellamanagementsummary.pdf (accessed January 20, 2011).
45. Bennett D, Burton A, Fishman S, Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: Management, Pharm Therap, 2005;30:354–61.
46. Abrahm JL, Assessing the patient in pain. In: Abrahm JL, ed. A Physician’s Guide to Pain and Symptom Management in Cancer Patients, 2nd edition, Baltimore, MD: Johns Hopkins University Press, 2005;107–47.
47. Van Dongen RT, Crul BJ, De Bock M, Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases, Pain, 1993;55:119–23.
48. Eisenach JC, DuPen S, Dubois M, et al., Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group, Pain, 1995;61:391–9.
49. Mercadante S, Agnello A, Armata MG, et al., The inappropriate use of the epidural route in cancer pain, J Pain Symptom Manage, 1997;13:233–7.
50. Davis MP, Acute pain in advanced cancer: an opioid dosing strategy and illustration, Am J Hosp Palliat Care, 2004;21:47–50.
51. Portenoy RK, Payne R, Coluzzi P, et al., Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study, Pain, 1999;79:303–12.
52. Coluzzi PH, Schwartzberg L, Conroy JD, et al., Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR), Pain, 2001;91:123–30.
53. Portenoy RK, Rapscak S, Kanner R, Tricyclic antidepressants in chronic pain, Pain, 1984;18:213–5.
US ONCOLOGY & HEMATOLOGY
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84